NeXstar Pharmaceuticals' AmBisome Is Subject Of Two Talks At ICAAC
AmBisome, a liposomal formulation of amphotericin B, has been shown to sterilize the CSF significantly earlier than conventional amphotericin B, with at least equal clinical efficacy and lower nephrotoxicity. In a randomized multi-center study, low-dose AmBisome therapy produced a response rate of 68% in treating invasive aspergillosis.